97 related articles for article (PubMed ID: 21522056)
21. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
J Pharmacol Exp Ther; 2002 Dec; 303(3):952-8. PubMed ID: 12438514
[TBL] [Abstract][Full Text] [Related]
22. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
[TBL] [Abstract][Full Text] [Related]
23. Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS.
Coles R; Kharasch ED
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 857(1):67-75. PubMed ID: 17656162
[TBL] [Abstract][Full Text] [Related]
24. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
[TBL] [Abstract][Full Text] [Related]
25. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
[TBL] [Abstract][Full Text] [Related]
26. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Nomoto M; Stahl S; Jenner P; Marsden CD
Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
[TBL] [Abstract][Full Text] [Related]
27. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
28. Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
Lincoln L; Fisher R; Jackson MJ; Jenner P; Neumeyer J; Sromek AW; Lees AJ; Rose S
Mov Disord; 2016 Sep; 31(9):1381-8. PubMed ID: 27133947
[TBL] [Abstract][Full Text] [Related]
29. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
30. Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine.
Teitelbaum AM; Flaker AM; Kharasch ED
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():239-53. PubMed ID: 27318149
[TBL] [Abstract][Full Text] [Related]
31. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
[TBL] [Abstract][Full Text] [Related]
32. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates.
Rose S; Scheller DK; Breidenbach A; Smith L; Jackson M; Stockwell K; Jenner P
Behav Pharmacol; 2007 Mar; 18(2):155-60. PubMed ID: 17351422
[TBL] [Abstract][Full Text] [Related]
33. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Kharasch ED; Mitchell D; Coles R
J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
[TBL] [Abstract][Full Text] [Related]
34. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
35. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Johnston TH; Huot P; Fox SH; Wakefield JD; Sykes KA; Bartolini WP; Milne GT; Pearson JP; Brotchie JM
J Pharmacol Exp Ther; 2011 Feb; 336(2):423-30. PubMed ID: 20966038
[TBL] [Abstract][Full Text] [Related]
36. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
Schneider JS; Van Velson M; Menzaghi F; Lloyd GK
Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
[TBL] [Abstract][Full Text] [Related]
37. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Lane EL; Cheetham SC; Jenner P
Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
[TBL] [Abstract][Full Text] [Related]
38. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
39. Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice.
Damaj MI; Grabus SD; Navarro HA; Vann RE; Warner JA; King LS; Wiley JL; Blough BE; Lukas RJ; Carroll FI
J Pharmacol Exp Ther; 2010 Sep; 334(3):1087-95. PubMed ID: 20576796
[TBL] [Abstract][Full Text] [Related]
40. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Ann Neurol; 1998 Apr; 43(4):507-13. PubMed ID: 9546333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
